BusinessEarth Science Tech Inc. Signs Contract with CDBQ to Advance Phase-2 Rollout on it’s CBD PatentsBy Nasdaq OMXAug 1, 2017, 12:25 PM UTC
BusinessEarth Science Tech, Inc. Targets Breast Cancer and Other Women's Health Issues in New Cannabis CBD-Based Pharmaceutical Drug Development InitiativesBy Nasdaq OMXApr 11, 2017, 11:45 AM UTC
BusinessETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.By Nasdaq OMXMar 6, 2017, 12:45 PM UTC
BusinessEarth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent StudiesBy Nasdaq OMXFeb 23, 2017, 11:45 AM UTC
BusinessETST and its wholly owned subsidiary, Cannabis Therapeutics, Signs Joint Venture with Smart Medicines GMP for the Development of its Cannabis Cannabinoid-Based Drugs & NutraceuticalsBy Nasdaq OMXFeb 14, 2017, 12:15 PM UTC
BusinessEarth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and TechnologyBy Nasdaq OMXFeb 6, 2017, 12:45 PM UTC
BusinessEarth Science Tech Announces Strategic Alliance with RRNP Healthcare and Dysfunctional Veterans of New Hampshire to conduct its First 30-Day PTSD Clinical Study with Veterans using ETST High Grade Hemp CBD (Cannabidiol) OilBy Nasdaq OMXMar 28, 2016, 12:00 PM UTC
BusinessEarth Science Tech Supported Positive Scientific Research Studies and Customer Feedback on its Phytocannabinoid-CBD (Cannabidiol) Rich Hemp Oil Prompts Company to Launch Non-Profit Phytocannabinoid-CBD Research FoundationBy Nasdaq OMXFeb 3, 2016, 12:45 PM UTC
